ClinicalTrials.gg
Active, not recruitingNCT06975878Updated Mar 2, 2026

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

A Phase 3 interventional study of PCV21 vaccine and Vaxneuvance vaccine in Pneumococcal Immunization and Healthy Volunteers, sponsored by Sanofi. Active, not recruiting at 49 sites in 8 countries. Open to participants aged 42 Days to 112 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,092
Allocation
Randomized
Ages
42 Days to 112 Days
Sex
All
01

Study summary

This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 15vPCV (Vaxneuvance, licensed pneumococcal conjugate vaccine) when they are administered with routine pediatric vaccines in infants aged from approximately 2 months (42 to 112 days).

The study duration per participant will be up to approximately 20 months. The study vaccines (either PCV21 or 15-valent pneumococcal vaccines) will be administered at approximately 2, 4, and 11 to 15 months of age or at approximately 2, 3, 4, and 11 to 15 months of age (for preterm infants). Routine pediatric vaccines will be given at the same timepoints, as per local practice / recommendations.

  • There will be 5 (for full-term infants) or 6 (for preterm infants) study visits:
  • Full-term infants: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 30 days, V04 at 11 months of age until 15 months of age, V05 separated from V04 by 30 days.
  • Preterm infants: Visit (V)01, V02 separated from V01 by 30 days, V03 separated from V02 by 30 days, V04 separated from V03 by 30 days, V05 at 11 months of age until 15 months of age, V06 separated from V05 by 30 days.
02

Conditions studied

  • Pneumococcal Immunization
  • Healthy Volunteers
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Days to 112 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Aged 42 to 112 days on the day of inclusion
  • Participants who are healthy as determined by medical evaluation including medical history and physical examination
  • Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg or born after a gestation period above 28 (> 28 weeks) through 36 weeks with a birth weight ≥ 1.5 kg, and in both cases medically stable as assessed by the investigator

Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic therapy
  • History of microbiologically confirmed Streptococcus pneumoniae infection or disease
  • Any to the routine pediatric vaccines being administered in the study
  • History of seizure or significant stable or progressive neurological disorders such as infantile spasms, inflammatory nervous system diseases, encephalopathy, cerebral palsy
  • Known systemic to any of the study interventions components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances
  • Laboratory-confirmed or known thrombocytopenia, as reported by the parent/legally acceptable representative (LAR), contraindicating intramuscular (IM) injection
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM injection
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Receipt of any vaccine in the 4 weeks preceding the study intervention administration or planned receipt of any vaccine in the 4 weeks following the study intervention administration, except for oral rotavirus vaccine, which may be received anytime during the study including at study visits and for influenza vaccination or meningococcal b vaccine, which may be received at least 14 days before or 14 days after any study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines, as applicable per local recommendations.
  • Previous vaccination against S. pneumoniae
  • Previous vaccination against the following antigens: diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and poliovirus
  • Receipt of more than 1 dose of vaccine
  • Receipt of immune globulins, blood or blood-derived products since birth
  • Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure

Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,092 participants (actual)

Study arms

  • Experimental
    Group 1: PCV21

    Participants will be administered via intramuscular injection (IM) a 2-dose primary series of PCV21 at approximately 2 and 4 months of age (MoA) or a 3-dose primary series (preterm infants) at 2, 3, and 4 MoA co- administered with Hexyon. At 11 to 15 MoA, participants will receive a 3rd dose or 4th dose (for preterm infants) of PCV21 co-administered with Hexyon and M M RvaxPro; Varivax will also be co-administered unless not possible as per local practice

    Biological: PCV21 vaccine · Biological: Hexyon vaccine · Biological: M-M-RvaxPro vaccine · Biological: Varivax vaccine

  • Active comparator
    Group 2: 15vPCV

    Participants will be administered via intramuscular injection (IM) a 2-dose primary series of 15vPCV at approximately 2 and 4 months of age (MoA) or a 3-dose primary series (preterm infants) at 2, 3, and 4 MoA co- administered with Hexyon. At 11 to 15 MoA, participants will receive a 3rd dose or 4th dose (for preterm infants) of 15vPCV co-administered with Hexyon and M M RvaxPro; Varivax will also be co-administered unless not possible as per local practice

    Biological: Vaxneuvance vaccine · Biological: Hexyon vaccine · Biological: M-M-RvaxPro vaccine · Biological: Varivax vaccine

Interventions

  • BiologicalPCV21 vaccine

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

    Also known as: 515

  • BiologicalVaxneuvance vaccine

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

    Also known as: Vaxneuvance ™

  • BiologicalHexyon vaccine

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

    Also known as: Hexyon®

  • BiologicalM-M-RvaxPro vaccine

    Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous

    Also known as: M-M-RVAX-PRO®

  • BiologicalVarivax vaccine

    Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous

    Also known as: Varivax®

06

What researchers measure

Primary outcomes

  1. Seroresponse rate for PCV21 and 15vPCV serotypes

    Serotype specific IgG concentration ≥ 0.35 µg/mL

    Time frame: 30 days post-toddler dose

  2. IgG concentration for PCV21 and 15vPCV serotypes

    Serotype specific IgG Geometric Mean Concentration (GMC)

    Time frame: 30 days post-toddler dose

Secondary outcomes

  1. Anti- hepatitis B surface antigen (HBsAg) Ab

    % Antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL)

    Time frame: 30 days post-toddler dose

  2. Anti- polyribosylribitol phosphate (PRP) Ab

    % Antibody concentrations ≥ 0.15 micrograms per milliliter (µg/mL)

    Time frame: 30 days post-toddler dose

  3. Anti-poliovirus types (1, 2, and 3) Ab

    % Antibody titers ≥ 1:8

    Time frame: 30 days post-toddler dose

  4. Anti-diphtheria Ab concentrations

    % Antibody concentration ≥ 0.1 IU/mL

    Time frame: 30 days post-toddler dose

  5. Anti-tetanus Ab concentrations

    % Antibody concentration ≥ 0.1 IU/mL

    Time frame: 30 days post-toddler dose

  6. Anti-pertussis Ab concentrations (Pertussis toxin (PT) and Filamentous Hemagglutinin (FHA))

    Antibody GMC

    Time frame: 30 days post-toddler dose

  7. Anti-measles Ab concentrations

    Antibody GMC

    Time frame: 30 days post-toddler dose

  8. Anti-mumps Ab concentrations

    Antibody GMC

    Time frame: 30 days post-toddler dose

  9. Anti-rubella Ab concentrations

    Antibody GMC

    Time frame: 30 days post-toddler dose

  10. Anti-varicella Ab concentrations

    Antibody GMC

    Time frame: 30 days post-toddler dose

  11. Anti HBsAg concentrations

    % Antibody concentrations ≥ 10 mIU/mL

    Time frame: 30 days post-primary series

  12. Anti-PRP Ab concentrations

    % Antibody concentrations ≥ 0.15 µg/mL

    Time frame: 30 days post-primary series

  13. Anti-poliovirus types (1, 2, and 3) Ab titers

    % Antibody titers ≥ 1:8

    Time frame: 30 days post-primary series

  14. Anti-diphtheria Ab concentrations

    % Antibody concentrations ≥ 0.1 IU/mL

    Time frame: 30 days post-primary series

  15. Anti-tetanus Ab concentrations

    % Antibody concentrations ≥ 0.1 IU/mL

    Time frame: 30 days post-primary series

  16. Anti-pertussis Ab concentrations (PT and FHA)

    Antibody GMC

    Time frame: 30 days post-primary series

  17. Serotype specific OPA titers for all serotypes included in PCV21

    Antibody Geometric mean titer (GMT)

    Time frame: 30 days post-primary series

  18. Serotype specific OPA titers for all serotypes included in PCV21

    Antibody GMT

    Time frame: 30 days post-toddler dose

  19. Presence of any immediate adverse events (AEs)

    Number of participants experiencing immediate AEs

    Time frame: Within 30 minutes after each vaccine injection

  20. Presence of solicited injection site and systemic reactions through 7 days after each vaccine injection

    Number of participants experiencing solicited injection site and systemic reactions

    Time frame: Through 7 days after each vaccine injection

  21. Presence of unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs through 30 days after each vaccine injection

    Number of participants experiencing unsolicited injection site reactions and unsolicited systemic AEs

    Time frame: Through 30 days after each vaccine injection

  22. Presence of serious adverse events (SAEs) throughout the study (through 6 months post- last vaccine injection)

    Number of participants experiencing SAEs

    Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 20 months

  23. Presence adverse events of special interest (AESIs) throughout the study (through 6 months post- last vaccine injection)

    Number of participants experiencing AESIs

    Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 20 months

07

Study locations

49 sites
  • Investigational Site Number : 0560004
    Alken, 3570, Belgium
  • Investigational Site Number : 0560001
    Bruges, 8000, Belgium
  • Investigational Site Number : 0560002
    Edegem, 2650, Belgium
  • Investigational Site Number : 0560005
    Gozée, 6534, Belgium
  • Investigational Site Number : 0560007
    Leuven, 3000, Belgium
  • Investigational Site Number : 0560003
    Roeselare, 8800, Belgium
  • Investigational Site Number : 2030001
    Jindřichův Hradec, 377 01, Czechia
  • Investigational Site Number : 2030009
    Krnov, 79401, Czechia
  • Investigational Site Number : 2030006
    Pilsen, 301 00, Czechia
  • Investigational Site Number : 2030008
    Prague, 18000, Czechia
  • Investigational Site Number : 2330001
    Paide, 72713, Estonia
  • Investigational Site Number : 2330004
    Tallinn, 10617, Estonia
  • Investigational Site Number : 2330002
    Tartu, 50106, Estonia
  • Investigational Site Number : 2460008
    Espoo, 02230, Finland
  • Investigational Site Number : 2460001
    Helsinki, 00100, Finland
  • Investigational Site Number : 2460010
    Helsinki, 00290, Finland
  • Investigational Site Number : 2460005
    Jarvenpaa, 04400, Finland
  • Investigational Site Number : 2460003
    Kokkola, 67100, Finland
  • Investigational Site Number : 2460004
    Oulu, 90220, Finland
  • Investigational Site Number : 2460002
    Seinäjoki, 60100, Finland
  • Investigational Site Number : 2460007
    Tampere, 33100, Finland
  • Investigational Site Number : 2460009
    Turku, 20520, Finland
  • Investigational Site Number : 2760005
    Herxheim, 76863, Germany
  • Investigational Site Number : 2760006
    Hürth, 50354, Germany
  • Investigational Site Number : 2760014
    Hürth, 50354, Germany
  • Investigational Site Number : 2760013
    Krefeld, 47799, Germany
  • Investigational Site Number : 2760010
    Mönchengladbach, 41236, Germany
  • Investigational Site Number : 2760012
    Mönchengladbach, 41236, Germany
  • Investigational Site Number : 2760008
    Schönau am Königssee, 83471, Germany
  • Investigational Site Number : 2760003
    Wolfsburg, 38448, Germany
  • Investigational Site Number : 3000001
    Athens, 11527, Greece
  • Investigational Site Number : 3000002
    Athens, 12462, Greece
  • Investigational Site Number : 3000006
    Ioannina, 45500, Greece
  • Investigational Site Number : 3000005
    Thessaloniki, 54642, Greece
  • Investigational Site Number : 3800004
    Rome, Lazio 00168, Italy
  • Investigational Site Number : 3800002
    Rome, Roma 00161, Italy
  • Investigational Site Number : 3800001
    Bari, 70124, Italy
  • Investigational Site Number : 3800008
    Foggia, 71122, Italy
  • Investigational Site Number : 3800010
    Lecce, 73100, Italy
  • Investigational Site Number : 3800007
    Milan, 20122, Italy
  • Investigational Site Number : 3800009
    Parma, 43126, Italy
  • Investigational Site Number : 6160001
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-048, Poland
  • Investigational Site Number : 6160007
    Torun, Kuyavian-Pomeranian Voivodeship 87-100, Poland
  • Investigational Site Number : 6160009
    Krakow, Lesser Poland Voivodeship 30-348, Poland
  • Investigational Site Number : 6160003
    Trzebnica, Lower Silesian Voivodeship 55-100, Poland
  • Investigational Site Number : 6160008
    Wroclaw, Lower Silesian Voivodeship 50-368, Poland
  • Investigational Site Number : 6160011
    Warsaw, Masovian Voivodeship 02-647, Poland
  • Investigational Site Number : 6160005
    Łomianki, Masovian Voivodeship 05-092, Poland
  • Investigational Site Number : 6160002
    Siemianowice Śląskie, Silesian Voivodeship 41-103, Poland
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Aug 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 16, 2025
StartActual
May 22, 2025
Primary completionEst.
Aug 25, 2027
CompletionEst.
Aug 25, 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06975878
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 16, 2025
Start date
May 22, 2025
Primary completion
Aug 25, 2027 (estimated)
Completion
Aug 25, 2027 (estimated)
Last update
Mar 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion